Latest news with #ROCHESTER
Yahoo
10-07-2025
- Business
- Yahoo
Geneticure Inc. Granted New U.S. Patent for Genetic Test to Predict Response in Renal Denervation for Hypertension
The patent supports the Company's broader mission to eliminate trial-and-error in treating hypertension (High Blood Pressure) with medications and medical devices. ROCHESTER, Minn., July 10, 2025--(BUSINESS WIRE)--Geneticure Inc., a leader in precision medicine for cardiovascular disease, announced today that the United States Patent and Trademark Office has granted U.S. Patent No. 12,351,873, for a Genetic-Based Weighted Algorithm Model for Predicting Response to Renal Denervation. This groundbreaking patent protects Geneticure's proprietary method of using a patient's genetic profile to predict their likelihood of benefiting from renal denervation — a minimally invasive procedure used to treat hypertension. "Renal denervation has demonstrated the ability to reduce blood pressure in certain patients, with other's experiencing no change or an increase in blood pressure post-denervation." said Scott Snyder, CEO of Geneticure. "Prior to Geneticure's research, a reliable method of predicting the response had not yet emerged and regardless of the denervation method, the changes in blood pressure have been variable across patient populations. Our technology has proven to identify the individuals most likely to respond, enabling more targeted use of this emerging therapy with increased prospects for adoption and payer coverage." The patented method leverages specific genetic markers combined with a proprietary weighted algorithm to determine responsiveness to renal denervation, enabling physicians to make informed treatment decisions beyond traditional risk-factor assessments. This newly issued patent expands Geneticure's growing intellectual property portfolio in the field of pharmacogenomics and device response prediction, further positioning the company at the forefront of personalized hypertension management. More on Geneticure for Renal Denervation: About Geneticure Geneticure Inc. is an Integrated Computational Genomic medicine company focused on eliminating the trial-and-error approach to treating chronic diseases. By integrating a patient's genetic information with physiologic insights, Geneticure provides physicians with actionable tools to optimize therapy selection and improve outcomes. The company's flagship offerings include genetic tests that predict response to common hypertension medications and now, response to renal denervation. View source version on Contacts Media Contact: Scott SnyderChief Executive OfficerGeneticure
Yahoo
10-07-2025
- Business
- Yahoo
Geneticure Inc. Granted New U.S. Patent for Genetic Test to Predict Response in Renal Denervation for Hypertension
The patent supports the Company's broader mission to eliminate trial-and-error in treating hypertension (High Blood Pressure) with medications and medical devices. ROCHESTER, Minn., July 10, 2025--(BUSINESS WIRE)--Geneticure Inc., a leader in precision medicine for cardiovascular disease, announced today that the United States Patent and Trademark Office has granted U.S. Patent No. 12,351,873, for a Genetic-Based Weighted Algorithm Model for Predicting Response to Renal Denervation. This groundbreaking patent protects Geneticure's proprietary method of using a patient's genetic profile to predict their likelihood of benefiting from renal denervation — a minimally invasive procedure used to treat hypertension. "Renal denervation has demonstrated the ability to reduce blood pressure in certain patients, with other's experiencing no change or an increase in blood pressure post-denervation." said Scott Snyder, CEO of Geneticure. "Prior to Geneticure's research, a reliable method of predicting the response had not yet emerged and regardless of the denervation method, the changes in blood pressure have been variable across patient populations. Our technology has proven to identify the individuals most likely to respond, enabling more targeted use of this emerging therapy with increased prospects for adoption and payer coverage." The patented method leverages specific genetic markers combined with a proprietary weighted algorithm to determine responsiveness to renal denervation, enabling physicians to make informed treatment decisions beyond traditional risk-factor assessments. This newly issued patent expands Geneticure's growing intellectual property portfolio in the field of pharmacogenomics and device response prediction, further positioning the company at the forefront of personalized hypertension management. More on Geneticure for Renal Denervation: About Geneticure Geneticure Inc. is an Integrated Computational Genomic medicine company focused on eliminating the trial-and-error approach to treating chronic diseases. By integrating a patient's genetic information with physiologic insights, Geneticure provides physicians with actionable tools to optimize therapy selection and improve outcomes. The company's flagship offerings include genetic tests that predict response to common hypertension medications and now, response to renal denervation. View source version on Contacts Media Contact: Scott SnyderChief Executive OfficerGeneticure
Yahoo
07-02-2025
- Climate
- Yahoo
Weather Forecast: More snow coming in through the weekend
ROCHESTER, NY (WROC) – A blast of snow this morning spit out an inch of fresh powder for the region, but blowing snow will make it seem like it's still snowing throughout this afternoon. There will be some clearing, but it's still cold as temperatures are in the 20s with wind chills in the 10s. Expect lake-effect snow along Route 104 through Wayne County that will spit out several more inches of snow this afternoon, but most will get missed. It is cold overnight and into Saturday, but there won't be any snow around through the afternoon. We wait for snow to come in Saturday night. The low tracks through Pennsylvania and we get an area-wide blanket of several inches going into Sunday morning. Expect a general 3-6″ with higher amounts possible in the Finger Lakes at on the hill tops. There will be some flakes lingering Sunday, but we should be below freezing throughout the weekend. There will be some lingering LES showers Monday, but accumulations should be minor. Tuesday is quiet, then we are watching Wednesday for the threat of snow. As of right now, the storm misses us to the south. If the trend is north, it could be another big snow. If that one doesn't verify, the next system Thursday and Valentine's Day Friday may verify with area-wide snow. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
